Single User - $1,498.00
Single Site - $1,875.00

Length
176 pages

Date published
April 2008

Additional info
Single-site, country, and global licenses are multi-user, searchable, and cut-and-paste ready PDFs delivered by e-mail.

Corporate subscriptions:
Contact
David Cunningham,
Global Report Sales
781-972-5472

Questions and to order by phone:
Contact Rose LaRaia
Customer Service
781-972-5444

Inflammatory Directions Report Table of Contents

INFLAMMATORY DIRECTIONS: STRATEGIES FOR SIX DISEASES WITH UNMET NEEDS

By Mark C. Via

Chapter 1
INTRODUCTION: THE IMMUNE SYSTEM AND THE INFLAMMATORY RESPONSE
1.1. The Immune System
1.2. Immune Dysfunction and Autoimmune Disease

Chapter 2
REVIEW OF THE INFLAMMATORY DISEASES: EPIDEMIOLOGY, PATHOLOGY, DIAGNOSIS, AND SYMPTOMS
2.1. Rheumatoid Arthritis
Pathology
Causes
Diagnosis
Epidemiology
2.2. Inflammatory Bowel Disease
Pathology
Causes
Diagnosis
Epidemiology
2.3. Psoriasis
Pathology
Causes
Diagnosis
Epidemiology
2.4. Lupus
Pathology
Causes
Diagnosis
Epidemiology
2.5. Multiple Sclerosis
Pathology
Causes
Diagnosis
Epidemiology
2.6. Asthma
Pathology
Causes
Diagnosis
Epidemiology

Chapter 3
CURRENT PHARMACOLOGICAL TREATMENT OPTIONS
3.1. Rheumatoid Arthritis
Analgesics and NSAIDS
Corticosteroids
Synthetic DMARDs
        Methotrexate
        Arava (Leflunomide)
        Other DMARDs
Biological DMARDs
        Enbrel (Etanercept)
        Remicade (Infliximab)
        Humira (Adalimumab)
        Kineret (Anakinra)
        Orencia (Abatacept)
        Rituxan (Rituximab)
3.2. Inflammatory Bowel Disease
Aminosalicylates
Corticosteroids
Immunomodulators
        Azathioprine, 6-Mercaptopurine, and 6-Thioguanine
        Methotrexate
        Cyclosporine
        Remicade (Infliximab)
        Humira (Adalimumab)
      Tysabri (Natalizumab)
Antibiotics
3.3. Psoriasis
Topical Therapies
        Corticosteroids
        Vitamin D3 and A Compounds
        Retinoids
        Coal Tar
        Anthralin
        Salicylic Acid
Light Therapy
Systemic Therapy
        Methotrexate
        Cyclosporine
        Oral Retinoids
        Hydroxyurea
        Amevive (Alefacept)
        Raptiva (Efalizumab)
        Enbrel (Etanercept)
        Remicade (Infliximab)
        Humira (Adalimumab)
3.4. Lupus
NSAIDs
Antimalarials
Corticosteroids
Immunomodulators
3.5. Multiple Sclerosis
Corticosteroids
Disease-Modifying Agents
        Interferon Beta
        Copaxone (Glatiramer Acetate)
        Novantrone (Mitoxantrone)
        Tysabri (Natalizumab)
Other Immunomodulators
3.6. Asthma
Quick-Relief Medications
        Bronchodilators
        Oral Corticosteroids
Long-Term Control Medications
        Inhaled Corticosteroids
        Bronchodilators
       Mast Cell Stabilizers
       Leukotriene Modifiers
       Xolair (Omalizumab)

Chapter 4
COMPOUNDS IN DEVELOPMENT: THE NEXT GENERATION OF DRUGS FOR INFLAMMATORY DISEASES
4.1. New Approaches to Inflammatory Diseases
Tumor Necrosis Factor Family Inhibitors
Interleukin Inhibitors
Other Cytokine Inhibitors
Chemokine Receptor Antagonists
Anti-inflammatory Cytokines
Compounds Targeting T-Cell Antigens
Compounds Targeting B-Cell Antigens
Complement Inhibitors
Adhesion Molecule Blockers
Protease Inhibitors
        TACE
        ICE
        Cathepsin S
Kinase Inhibitors
       p38 MAP Kinase
        JNK
        NF-κB
Other Kinases
4.2. Setbacks
4.3. Rheumatoid Arthritis
TNF-alpha Inhibitors
        UCB
        Centocor
        Targeted Genetics
        Arana Therapeutics
        Xencor
        Meyer Pharmaceuticals
        Pharmaxis
        Ception Therapeutics
        Ablynx
        Nastech Pharmaceutical
        Devgen
Interleukin Inhibitors
        Amgen
Kinase Inhibitors
        Rigel Pharmaceuticals
        Plexxikon
4.4. Inflammatory Bowel Disease
Adhesion Molecule Blockers
        Atlantic Healthcare
        Millennium Pharmaceuticals
Other Compounds
        InDex Pharmaceuticals
        Genzyme
4.5. Psoriasis
TNF Inhibitors
        Apollo Life Sciences
        York Pharma
Interleukin Inhibitors
        Centocor
        Abbott Laboratories
Calcineurin Inhibitors
        Isotechnika
        Biogen Idec
        CombinatoRx
        Celgene
Vitamin D Analogs
        CollaGenex Pharmaceuticals
        Cytochroma
4.6. Lupus
Immunomodulators
       La Jolla Pharmaceutical
        Genelabs Technologies
BLyS Inhibitors
        Human Genome Sciences
       ZymoGenetics
        Anthera Pharmaceuticals
        Biogen Idec/Genentech
        Xencor
Toll-like Receptor Antagonists
        Coley Pharmaceutical Group
        Dynavax Technologies
        Idera Pharmaceuticals
4.7. Multiple Sclerosis
Immunomodulators
        Biogen Idec
        Genzyme/Bayer Schering Pharma
        Novartis
Cytokines
        Nastech Pharmaceutical
        Syntonix Pharmaceuticals
        Ichor Medical Systems
        Nautilus Biotech
        Flamel Technologies
        Modigene
        Bolder BioTechnology
        CoGenesys
        Allozyne
Peptide Vaccines and MBP-Base Therapeutics
        Orchestra Therapeutics
        BioMS Medical/Eli Lilly
        Bayhill Therapeutics
Remyelinating Agents
        Biogen Idec
        Acorda Therapeutics
4.8. Asthma
Interleukin Inhibitors
       GlaxoSmithKline
       MedImmune/BioWa
       Aerovance
       Amgen
       Genentech
       Altair Therapeutics
       CSL/Merck
       Synairgen
    Phosphodiesterase-4 Inhibitors
        Nycomed
        Glenmark Pharmaceuticals/Forest Laboratories
        MediciNova
        Other PDE4 Inhibitors
Toll-like Receptor Agonists
        Coley Pharmaceutical Group/Sanofi-Aventis
       Dynavax Technologies
        Idera Pharmaceuticals
        InDex Pharmaceuticals
CRTH2 Antagonists

References

Company Index with Web Addresses

Reports
CHI